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Abstract 6-Sulfo-sialyl Lewis X structure is attributable to
recognition between lymphocytes and high endothelial venules.
However, the biosynthetic pathway still remains unclear. We
found that a L-galactosyltransferase (LGalT) in human colo-
rectal mucosa preferentially acts on GlcNAc-6-O-sulfate (6S-
GN). 6S-GN:L4GalT was partially purified by UDP-hexanol-
amine-Sepharose and asialo-agalacto-ovomucin-Sepharose chro-
matographies. The optimum pH of this enzyme was found to be
6.5^7.5 and the Michaelis constants for 6S-GN and UDP-Gal
were 0.43 mM and 16 WM, respectively. The enzymatic activity
was dependent on divalent cations and the substrate specificity
was not affected by K-lactalbumin. This is the first demonstration
of the occurrence of 6S-GN:L4GalT.
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1. Introduction
Sulfate residues at the C-6 position of GlcNAc have been
found in various N-linked- and O-linked glycan chains.
Although the biological roles of most sulfated glycans still
remain unclear, it has been reported that the GlcNAc-6-O-
sulfate moiety in the 6-sulfo-sialyl Lewis X structure is impor-
tant for binding of lymphocytes to high endothelial venules in
lymph nodes [1,2]. Sulfation at the C-6 of GlcNAc is catalyzed
by GlcNAc:C6 sulfotransferase (SulT). The enzyme cannot
act on internal GlcNAc residues such as GalL1C4Glc-
NAcL1C, but acts on non-reducing terminal GlcNAc [3^5].
The GlcNAc-6-O-sulfate is sequentially converted to
GalL1C 4(SO33 C 6)GlcNAc by L1C 4galactosyltransferase
(GalT) [3^5]. However, the galactosylation has not yet been
studied enzymologically and some ambiguities exist with re-
spect to the biosynthesis of the GalL1C 4(SO33 C 6)GlcNAc
structure.
In preliminary experiments, we noticed that L4GalT activity
in human colorectal mucosa might be attributable to a mix-
ture of several enzymes. We show in this paper that L4GalTs
derived from crude microsomal fractions of colorectal mucosa
can be separated into at least two components, one of which
preferentially recognizes GlcNAc-6-O-sulfate (6S-GN) as a
substrate. The demonstration that a L1,4-galactosyltransferase
recognizes terminal GlcNAc-6-O-sulfate on a number of ac-
ceptors represents a signi¢cant advance in our understanding
of the synthesis of 6-sulfo-sialyl Lewis X structures.
2. Materials and methods
2.1. Materials and enzymes
Uridine diphosphate [3H]galactose {UDP-Gal, galactose-4,5-
[3H](N)} (1.79 TBq/mmol) was purchased from DuPont/NEN (Bos-
ton, MA). UDP-Gal, UDP, human K-lactalbumin, bovine milk
L1,4GalT were purchased from Sigma Chemical Co. (St. Louis,
MO). Ricinus communis agglutinin (RCA)120-agarose (4.1 mg protein
per ml gel) was purchased from Seikagaku Co. (Tokyo, Japan).
GlcNAcL1C3GalL1C 4Glc(GL) and Neu5AcK2C6GlcNAcL1
C 3GalL1C 4Glc (agalacto-LST-b) were prepared from lacto-N-tet-
raose and LST-b [6], respectively, by Streptococcus 6646K L-galacto-
sidase digestion. GlcNAcL1C2ManK1C 3(GlcNAcL1C 2ManK1
C 6)ManL1C 4GlcNAcL1C 4GlcNAc (GP) was prepared from
egg yolk glycopeptide SGP [7] by sequential steps of hydrazinolysis-
re-N-acetylation, mild acid hydrolysis, and Streptococcus 6646K L-
galactosidase digestion. N-Acetyl-D-glucosamine-6-O-sulfate (6S-GN)
was prepared from D-glucosamine-6-O-sulfate (Sigma) by N-acetyl-
ation [8]. SO33 C 6GlcNAcL1C 2ManK1C 3(ManK1C 6)ManL1
C4GlcNAcL1C4(FucK1C6)GlcNAc (6S-GP) was prepared from
porcine thyroglobulin (Sigma) [9] by sequential steps of pronase E
digestion, hydrazinolysis-re-N-acetylation, and digestion with Arthro-
bacter ureafaciens sialidase, Streptococcus 6646K L-galactosidase, and
jack bean L-N-acetylhexosaminidase.
2.2. Preparation of a⁄nity resins
UDP-hexanolamine (Sigma) was conjugated to CNBr-activated Se-
pharose 4B (Pharmacia Biotech, Sweden). The amount conjugated
was 7 Wmol of UDP-hexanolamine per ml of gel.
Ovomucin was prepared from egg white according to the method of
Brooks and Hale [10], and digested sequentially with pronase E, Sal-
monella typhimurium LT2 K2,3-sialidase and Streptococcus 6646K L-
galactosidase. Asialo-agalacto-ovomucin glycopeptides obtained were
conjugated with CNBr-activated Sepharose 4B. The amount conju-
gated was 6.7 mg per ml of gel.
2.3. Assay of GL:L3GalT and GL:L4GalTs
The assay was performed by the method described previously [11].
Brie£y, a 4 Wl reaction mixture consisting of 50 mM HEPES-NaOH
bu¡er (pH 7.2), 10 mM MnCl2, 0.5% (v/v) Triton X-100, 0.5 WM
UDP-[3H]Gal (2.2U105 dpm), 130 WM UDP-Gal, acceptor oligosac-
charides, 1 mM dithiothreitol (DTT) and enzymes, was incubated at
37‡C for 20 min. 3H-Labeled products were puri¢ed by paper electro-
phoresis and paper chromatography. The [3H]Gal residue linkage was
determined by RCA120-agarose a⁄nity chromatography [12].
2.4. Separation of colorectal LGalTs
The normal mucosal tissue was obtained from an area at least a
10 cm distance from the margin of the carcinoma of patients under-
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going surgical resection, and was separated completely from the
muscle layer and stored frozen at 380‡C before use. The procedure
of microsome preparation was described previously [11]. Crude micro-
somes derived from 10 individuals (17.3 g) were suspended in 8 ml of
20 mM HEPES-NaOH (pH 7.3), 10 mM MnCl2, 20% (v/v) glycerol,
and 1 mM DTT (bu¡er A) containing 0.15 M NaCl and 1% (v/v)
Triton X-100, and the sample was gently stirred for 1 h. After ultra-
centrifugation, the precipitate was further extracted twice and three
detergent-extracted fractions were collected. The fraction was dialyzed
against bu¡er A and applied to an UDP-hexanolamine-Sepharose
column (1.6U3 cm; equilibrated with bu¡er A containing 0.1% Triton
X-100 (bu¡er B); £ow rate: 10 ml/h). After washing with bu¡er B,
LGalT activities were eluted with bu¡er B containing 1 M NaCl
(fraction I) and thereafter bu¡er B containing 1 M NaCl and 1 mM
UDP (fraction II). Each of the fractions was dialyzed against bu¡er A
and rechromatographed. Fraction I was further applied to an asialo-
agalacto-ovomucin-Sepharose column (0.7U2.6 cm; equilibrated with
bu¡er B; £ow rate: 10 ml/h). After washing with bu¡er B, LGalT
activity was eluted by applying a linear gradient of NaCl (0^0.2 M) in
bu¡er B and thereafter bu¡er B containing 0.5 M NaCl. The protein
contents were estimated using the Bio-Rad Protein Assay dye reagent
with bovine serum albumin as a standard.
3. Results and discussion
3.1. Partial puri¢cation of human colorectal 6S-GN:L4GalT
LGalTs in crude microsomes of human colorectal mucosa
were extracted three times with 1% Triton X-100. When the
supernatant fractions were applied to UDP-hexanolamine-Se-
pharose a⁄nity chromatography, the GL:LGalT activity was
separated into two fractions, I and II, as shown in Fig. 1A.
Fraction I was eluted with 1 M NaCl and contained mainly
GL:L3GalT activity. Fraction II was eluted with 1 mM UDP/
1 M NaCl and contained only GL:L4GalT. The linkages of
[3H]Gal in the products were determined by RCA120-agarose
lectin column chromatography [12] ; [3H]GalL1C3GL was
retarded, and [3H]GalL1C 4GL bound to the column and
was eluted with 10 mM lactose. When 6S-GN was used as
acceptor, a single type of LGalT activity was found in fraction
I (Fig. 1A). It was suggested that not only L3GalT but also
6S-GN-speci¢c LGalT exists in fraction I. This fraction was
rechromatographed and then applied to an asialo-agalacto-
ovomucin-Sepharose column, because ovomucin contains a
GalL1C 4(SO33 C 6)GlcNAc moiety in the region peripheral
to the O-linked chains [13]. As shown in Fig. 1B, two types of
LGalTs, 6S-GN:LGalT (O in Fig. 1B) and GL:L3GalT (b in
Fig. 1B), were separated from each other. The yield of 6S-
GN:LGalT from crude extract is summarized in Table 1.
The linkage of [3H]Gal in the enzyme product,
[3H]GalC (SO33 C 6)GlcNAc, was determined by two meth-
ods. First, upon digestion with L1C4 speci¢c diplococcal
L-galactosidase, [3H]Gal was released from [3H]GalC
(SO33C6)GlcNAc. Second, after mild methanolysis (0.05 N
HCl/MeOH, 25‡C, 4 h) [14], the desulfated product [3H]Gal-
GlcNAc was bound to an RCA120-agarose column and eluted
with 10 mM lactose-PBS, indicating that [3H]Gal is linked to
the C-4 position of the GlcNAc residue. These results indicate
that this enzyme is 6S-GN:L4GalT. Next, the biochemical
properties of the 6S-GN:L4GalT in human colorectal mucosa
were investigated.
3.2. The biochemical properties of 6S-GN:L4GalT
The reaction rate was proportional to protein concentration
(at least 1 mg/ml of protein) under the standard conditions
employed and was linear for at least 2 h (data not shown).
The activity of the enzyme as a function of pH is shown in
Fig. 2A. The optimum pH was within the range of pH 6.5^
7.5. From a double reciprocal plot of the substrate concen-
tration (6S-GN) versus reaction rate, the Km and Vmax values
for 6S-GN were calculated to be 0.43 mM and 450 nmol/min/
mg protein, respectively (data not shown). Furthermore, Km
and Vmax values for UDP-Gal were calculated to be 16 WM
and 450 nmol/min/mg protein, respectively (data not shown).
The relative activity in the presence of various compounds
is shown in Fig. 2B. The enzyme was inhibited by 5 mM
EDTA (O), suggesting that 6S-GN:L4GalT is dependent on
divalent cations. MnCl2, MgCl2, and CaCl2 were good acti-
vators of 6S-GN:L4GalT (S, P, and E, respectively in Fig.
2B). 6S-GN:L4GalT activity was inhibited by 10 mM NEM
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Fig. 1. A: Chromatography of a Triton X-100-extracted fraction
containing LGalT activities on UDP-hexanolamine-Sepharose. The
column (1.6U3 cm) was washed (each 18-ml fraction) with bu¡er B
followed by bu¡er B containing 1 M NaCl and then bu¡er B con-
taining 1 M NaCl-1 mM UDP. Protein (R), GL:L3GalT (b ; 1 = 10
nmol/min/ml), GL:L4GalT (a ; 1 = 1 nmol/min/ml) and 6S-GN:
L4GalT (O ; 1 = 1 nmol/min/ml) were assayed as described in Sec-
tion 2. B: Chromatography of fraction I containing L3GalT and
6S-GN:L4GalT on asialo-agalacto-ovomucin-Sepharose. The column
(0.7U2.6 cm) was eluted (each 2-ml fraction) with bu¡er B followed
by a linear gradient of NaCl (dotted line) and thereafter 0.5 M
NaCl in bu¡er B.
Table 1
Partial puri¢cation of 6S-GN:L4GalT from human colorectal mucosa
Step Total protein
(mg)
Total activity
(nmol/min)
Speci¢c activity
(nmol/min/mg)
Yield
(%)
Puri¢cation
(fold)
Crude extract 568 68.8 0.121 100 ^
Microsome 142 61.9 0.436 90 3.6
First UDP-hexanolamine-Sepharose 1.93 31.0 16.1 45 133
Second UDP-hexanolamine-Sepharose 0.176 30.8 175 45 1450
Asialo-agalacto-ovomucin-Sepharose 0.038 15.1 397 22 3280
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(F), showing only 18% of the control level (10 mM MnCl2),
suggesting that the enzyme has thiol residues which are im-
portant for activity.
The substrate speci¢city of 6S-GN:L4GalT was investigated
in comparison with L3GalT (b in Fig. 1B) and L4GalTs (frac-
tion II in Fig. 1A) using various acceptors. As summarized in
Table 2, when GL, GP, or GlcNAc was used as the acceptor,
6S-GN:L4GalT showed only weak activity. In contrast, when
6S-GN or 6S-GP was used as the acceptor, each of these
substrates was recognized as a good acceptor by 6S-
GN:L4GalT. However, 6S-GN:L4GalT did not recognize
Neu5AcK2C 6GlcNAcL1C 3GalL1C 4Glc as a good ac-
ceptor. These results show that the enzyme displays strict
substrate speci¢city limited to SO33 C 6GlcNAc-R and it
was categorized as 6S-GN:L4GalT. To the best of our knowl-
edge, this is the ¢rst demonstration of the occurrence of a 6S-
GN-speci¢c L4GalT. Its character is very di¡erent from that
of other LGalTs including GL:L3GalT (b in Fig. 1B) and
L4GalTs (fraction II in Fig. 1A). L3GalT preferentially recog-
nizes GL, while L4GalTs broadly recognize GL, GP, and
GlcNAc, however, they do not recognize 6S-GN or 6S-GP
as good substrates. The substrate speci¢cities of the L4GalTs
in human colorectal mucosa (fraction II in Fig. 1A) are sim-
ilar to those of L4GalT in bovine milk, which is categorized as
L4GalTI. In the presence of K-lactalbumin, 6S-GN:L4GalT
activity with 6S-GN as the substrate did not change (Fig.
2C, W) and 6S-GN:L4GalT did not show any activity with
Glc as the substrate, (Fig. 2C, 8), whereas L4GalTs (fraction
II in Fig. 1A) and bovine milk LGalT I activities with glucose
as the substrate markedly increased (Fig. 2C, C and D, re-
spectively).
Recently cDNAs for L4GalTs other than L4GalTI have
been cloned and sequenced [15^19]. Almeida et al. [17] iso-
lated cDNAs for L4GalTII and L4GalTIII, and showed that
L4GalTII is similar to L4GalTI in terms of the e¡ect of K-
lactalbumin and that L4GalTIII activity is not in£uenced sub-
stantially by K-lactalbumin. Sato et al. [18] isolated a cDNA
for L4GalT, which shows a rather strict substrate speci¢city
limited to N-linked glycans. However, it is unclear whether or
not the L4GalTs can preferentially galactosylate 6S-GN resi-
dues. It should be resolved in a subsequent study whether 6S-
GN:L4GalT is distinct from the six L4GalTs so far reported.
The GalL1C4(SO33C6)GlcNAc structure is broadly dis-
tributed in O-linked and N-linked glycans of various glyco-
proteins. The extensive distribution of this structure suggests
that 6S-GN:L4GalT could occur in various tissues. In biosyn-
thesis of the GalL1C 4(SO33 C 6)GlcNAc structure, it seems
to be important which residue is ¢rst transferred to the non-
reducing GlcNAc, L1C 4-linked Gal or C6-linked SO33 . We
recently found that GlcNAcL1C2Man is a good substrate for
human colorectal mucosa GlcNAc:C6SulT (A. Seko, S. Yo-
nezawa, T. Utsunomiya and K. Yamashita, submitted). It has
been shown that non-reducing GlcNAcL1C is a much better
substrate for GlcNAc:C 6SulTs from rat organs and human
respiratory mucus than GalL1C4GlcNAcL1C [3^5]. These
results indicate that the L1C 4-galactosylation follows sulfa-
tion at the C-6 of GlcNAc residues and L1C4-galactosylation
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Fig. 2. E¡ects of pH (A), divalent cations (B) and K-lactalbumin
(C) concentration on 6S-GN:L4GalT activity. A: The pH e¡ect was
analyzed using 50 mM sodium cacodylate bu¡er (pH 5.90^6.83, b),
50 mM HEPES-NaOH bu¡er (pH 6.66^8.12, a) or 50 mM TAPS-
NaOH bu¡er (pH 8.19^8.49, R). B: The enzymatic activity was as-
sayed in the presence of indicated concentrations of MnCl2 (S),
MgCl2 (P), or CaCl2 (E). The enzymatic activity displayed in the
presence of 5 mM EDTA (O) or upon preincubation at 4‡C for
10 min in the presence of 5 mM NEM and 10 mM MnCl2 (F) is
also indicated. C: L4GalTs (fraction II in Fig. 1A) (C), bovine milk
L4GalT (D), and 6S-GN:L4GalT (8) activities using 20 mM Glc as
acceptor were assayed in the presence of indicated concentrations of
human K-lactalbumin and are indicated relative to the activity of
bovine milk L4GalT in the presence of 1.0 mg/ml K-lactalbumin as
100%. 6S-GN:L4GalT activity (W) using 3 mM 6S-GN as acceptor
was also assayed and is indicated relative to the activity in the pres-
ence of 1.0 mg/ml K-lactalbumin as 100%.
Table 2
Substrate speci¢cities of human colorectal L-galactosyltransferases
Substratea 6S-GN:L4GalT
(O in Fig. 1B)
L3GalT
(b in Fig. 1B)
L4GalTs
(fraction II in Fig. 1A)
Bovine milk
L4GalT
GlcNAcL1C 3GalL1C 4Glc (GL) 3.9 100 100 100
GlcNAc2WMan3WGlcNAc2 (GP) 2.9 0.5 90 95
GlcNAc 1.1 1.5 43 60
SO33 C 6GlcNAc (6S-GN) 100 0 2.0 1.1
SO33 C 6GlcNAcWMan3WGlcNAcWFucWGlcNAc (6S-GP) 129 0 8.3 13.1
Neu5AcK2C 6GlcNAcL1C 3GalL1C 4Glc 9.1 2.5 2.6 4.7
aThe substrate concentration was 1 mM in each instance.
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of the GalL1C 4(SO33 C 6)GlcNAc structure may be specif-
ically catalyzed by 6S-GN:L4GalT.
It has been reported that L-selectin and their glycan ligands
are involved in the attachment of leukocytes to high endothe-
lial venules in lymph nodes. It was reported that sulfated sialyl
Lewis X containing a Gal-6-O-sulfate or GlcNAc-6-O-sulfate
moiety occurs in endothelial glycoproteins and serves as a
good ligand for L-selectin [1,2,20]. It still remains unclear
which glycosyltransferases are rate-limiting in the biosynthesis
of sulfated glycans. It might be speculated that
GlcNAc:C6SulT or 6S-GN:L4GalT, which is likely to be
involved in the early steps of biosynthesis, might play an
important role in expression of the 6-sulfo-sialyl Lewis X
structure. The possible biosynthetic pathway is considered to
be as follows:
Cloning of the genes encoding GlcNAc:C 6SulT and 6S-
GN:L4GalT will open the way to resolving the regulatory
mechanism of the biosynthesis of the sulfated glycans.
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